Clinical Trials
11 trialsNCT04617522 2026-06-02
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Gilead Sciences
Phase 1 Recruiting
NCT06167317 2026-05-28
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT07461454 2026-05-26
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Recruiting
NCT06801834 2026-05-20
EVOKE-SCLC-04
Gilead Sciences
Phase 3 Recruiting
NCT05633654 2026-04-30
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences
Phase 3 Recruiting
NCT07533123 2026-04-16
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT03547973 2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2 Recruiting
NCT06926920 2026-01-30
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Gilead Sciences
Phase 1/2 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06827613 2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting